Higher Altitudes, Higher Hemoglobin: Mapping Switzerland’s Topography and Hemoglobin Levels
Even small increases in residential altitude significantly elevated blood hemoglobin (Hb) and ferritin levels in young men living in Switzerland, according to a study...
Germline RUNX1 Mutations in RUNX1-Mutated AML More Frequent Than Previously Thought
A small study in Canada shows that the frequency of germline RUNX1 mutations in patients with RUNX1-mutated acute myeloid leukemia (AML) is higher than...
Patients With SCD and TP53 Mutations May Develop Myeloid Malignancy After Unsuccessful AlloHCT
Population studies have shown that patients with sickle cell disease (SCD) who have undergone an unsuccessful allogeneic hematopoietic cell transplantation (alloHCT) have an increased...
Blinatumomab Leads to High Remission Rate in Infants With Persistent MRD-Positive ALL
Treatment with the bispecific CD19/CD3 antibody blinatumomab induced molecular remissions in most infants with persistent measurable residual disease (MRD)–positive acute lymphocytic leukemia (ALL), according...
Avadomide Shows Promising Clinical Activity and Tolerability in Relapsed/Refractory DLBCL
Avadomide monotherapy demonstrated preliminary clinical efficacy in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), according to results from a phase I...
Peripherally Inserted Central Catheters Sharply Increase Risk of Childhood VTE Events
In children who received central venous catheters, peripherally inserted central catheters (PICCs) appear to be associated with a higher risk of venous thromboembolism (VTE),...
Can a CAR T-Cell “Cocktail” Overcome Antigen Escape?
A sequential infusion of 2 third-generation chimeric antigen receptor (CAR) T cells targeting CD19 and CD22, respectively, was associated with a high response rate...
Novel JAK2 Insertion/Deletion Mutation Associated With Unique MPN Overlap Syndrome
In a small study of patients with myeloproliferative neoplasms (MPNs), a novel JAK2 insertion/deletion mutation, which the investigators termed JAK2ex13InDel, was found to drive...
Updates From ECHELON-1: Brentuximab Vedotin Provides Durable Efficacy in Hodgkin Lymphoma
Previously reported results from the phase III ECHELON-1 trial suggested that replacing bleomycin with brentuximab vedotin in the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)...
Achievement of MRD Negativity Predicts Favorable Prognosis in RUNX1-RUNX1T1+ AML
In patients with acute myeloid leukemia (AML) with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1+ fusion, serial assessment of measurable residual disease (MRD) can identify people at a high risk...
Current Issue
April 2020, Volume 6, Issue 5
This issue examines immunization guidelines for patients with hematologic disorders, considers medical education amid the coronavirus pandemic, and more.
